Nothing Special   »   [go: up one dir, main page]

SG11201403956VA - Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines - Google Patents

Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines

Info

Publication number
SG11201403956VA
SG11201403956VA SG11201403956VA SG11201403956VA SG11201403956VA SG 11201403956V A SG11201403956V A SG 11201403956VA SG 11201403956V A SG11201403956V A SG 11201403956VA SG 11201403956V A SG11201403956V A SG 11201403956VA SG 11201403956V A SG11201403956V A SG 11201403956VA
Authority
SG
Singapore
Prior art keywords
oxazines
fluoromethyl
dihydro
Prior art date
Application number
SG11201403956VA
Other languages
English (en)
Inventor
Hans Hilpert
Roland Humm
Thomas Woltering
Original Assignee
Hoffmann La Roche
Siena Biotech Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Siena Biotech Spa filed Critical Hoffmann La Roche
Publication of SG11201403956VA publication Critical patent/SG11201403956VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201403956VA 2012-01-26 2013-01-23 Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines SG11201403956VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152686 2012-01-26
PCT/EP2013/051166 WO2013110622A1 (en) 2012-01-26 2013-01-23 Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines

Publications (1)

Publication Number Publication Date
SG11201403956VA true SG11201403956VA (en) 2014-10-30

Family

ID=47603713

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403956VA SG11201403956VA (en) 2012-01-26 2013-01-23 Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines

Country Status (24)

Country Link
US (1) US9067926B2 (xx)
EP (1) EP2807155B1 (xx)
JP (1) JP5869151B2 (xx)
KR (1) KR101669349B1 (xx)
CN (1) CN104066727B (xx)
AR (1) AR089781A1 (xx)
AU (1) AU2013211646B2 (xx)
BR (1) BR112014015630B1 (xx)
CA (1) CA2856892C (xx)
CL (1) CL2014001838A1 (xx)
CO (1) CO6960553A2 (xx)
CR (1) CR20140306A (xx)
EA (1) EA027059B1 (xx)
HK (1) HK1197242A1 (xx)
IL (1) IL232764A (xx)
MA (1) MA35748B1 (xx)
MX (1) MX354173B (xx)
NZ (1) NZ625684A (xx)
PE (1) PE20142376A1 (xx)
PH (1) PH12014501334A1 (xx)
SG (1) SG11201403956VA (xx)
TW (1) TWI472528B (xx)
UA (1) UA113538C2 (xx)
WO (1) WO2013110622A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
JP2016501827A (ja) * 2012-10-24 2016-01-21 塩野義製薬株式会社 Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
BR112015016315A2 (pt) * 2013-01-22 2017-07-11 Hoffmann La Roche fluoro-[1,3]oxazinas como inibidores de bace1
TW201446758A (zh) 2013-03-01 2014-12-16 Amgen Inc 作爲β-分泌酶抑制劑的全氟化5,6-二氫-4H-1,3-□-2-胺化合物及其用途
EP2964644B1 (en) 2013-03-08 2018-12-26 Amgen, Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US11447478B2 (en) 2013-04-11 2022-09-20 Hoffmann-La Roche Inc. BACE1 inhibitors
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有bace1抑制活性之二氫噻及二氫衍生物
WO2016001266A1 (en) 2014-07-04 2016-01-07 F. Hoffmann-La Roche Ag Fluoro-[1,3]oxazines as bace1 inhibitors
EP3177618A1 (en) 2014-08-08 2017-06-14 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
MX2017012188A (es) 2015-03-20 2017-12-15 Hoffmann La Roche Inhibidores de beta-secretasa 1 (bace1).
WO2017061534A1 (en) 2015-10-08 2017-04-13 Shionogi & Co., Ltd. Dihydrothiazine derivatives
JP2017071603A (ja) * 2015-10-09 2017-04-13 塩野義製薬株式会社 ジヒドロチアジンまたはジヒドロオキサジン誘導体を含有する医薬組成物
BR112020021728A2 (pt) 2018-04-27 2021-01-26 Shionogi & Co., Ltd. derivados de tetra-hidropiranooxazina tendo atividade inibitória de bace1 seletiva
CN111892550B (zh) * 2020-08-25 2022-07-19 苏州大学 4-苯基-6h-1,3-噁嗪-6-酮衍生物及其制备和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572263T3 (es) * 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
US20100035865A1 (en) * 2007-04-03 2010-02-11 Pfizer Inc Sulfonamides and Pharmaceutical Compositions Thereof
US8653067B2 (en) * 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
KR20100017255A (ko) * 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
AR077328A1 (es) * 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
US8188079B2 (en) * 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US20120238557A1 (en) * 2009-11-13 2012-09-20 Shionogi & Co., Ltd. Aminothiazine or aminooxazine derivative having amino linker
UA103272C2 (xx) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2$2-амино-5,5-дифтор-5,6-дигидро-4h-оксазины как ингибиторы bace1 и/или bace2
BR112012013854A2 (pt) * 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
WO2011071109A1 (ja) * 2009-12-11 2011-06-16 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9067924B2 (en) 2011-03-04 2015-06-30 Hoffmann-La Roche Inc. 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
US8754075B2 (en) * 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors

Also Published As

Publication number Publication date
AR089781A1 (es) 2014-09-17
MX354173B (es) 2018-02-16
AU2013211646B2 (en) 2017-09-14
JP5869151B2 (ja) 2016-02-24
PH12014501334B1 (en) 2014-09-15
CN104066727B (zh) 2019-04-26
CA2856892A1 (en) 2013-08-01
IL232764A0 (en) 2014-07-31
US20150031690A1 (en) 2015-01-29
BR112014015630B1 (pt) 2022-05-17
US9067926B2 (en) 2015-06-30
HK1197242A1 (en) 2015-01-09
CA2856892C (en) 2020-05-12
MA35748B1 (fr) 2014-12-01
EA027059B1 (ru) 2017-06-30
EP2807155B1 (en) 2017-04-12
BR112014015630A2 (pt) 2017-06-13
KR20140117625A (ko) 2014-10-07
JP2015504906A (ja) 2015-02-16
AU2013211646A1 (en) 2014-06-05
PE20142376A1 (es) 2015-01-17
UA113538C2 (xx) 2017-02-10
EP2807155A1 (en) 2014-12-03
CN104066727A (zh) 2014-09-24
WO2013110622A1 (en) 2013-08-01
EA201491321A1 (ru) 2014-11-28
IL232764A (en) 2015-10-29
TWI472528B (zh) 2015-02-11
KR101669349B1 (ko) 2016-10-25
PH12014501334A1 (en) 2014-09-15
CR20140306A (es) 2014-11-17
CO6960553A2 (es) 2014-05-30
CL2014001838A1 (es) 2014-11-07
BR112014015630A8 (pt) 2021-03-16
MX2014008446A (es) 2015-02-24
TW201335153A (zh) 2013-09-01
NZ625684A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
IL232764A0 (en) Fluoromethyl-6,5- - dihydro-1,34]-h]oxazine
HK1208443A1 (en) 2,3-benzodiazepines 23-
GB201304967D0 (en) .
GB201204183D0 (en) .
EP2935214A4 (en) 1,4-PYRIDONES COMPOUNDS
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
HK1192757A1 (zh) 取代的 -芳基- -苯基- -三嗪- -胺
ZA201503682B (en) 3,3'-dinitro-5,5'-bistriazole-1,1'-diol
HK1207317A1 (en) Substituted 1,6-naphthyridines 16-
HUE041320T2 (hu) 1,3-Specifikus intraészterezés
IL237542B (en) Amphiphilic compounds, their preparations and uses
IL280316B (en) Amphiphilic compounds, preparations and their use
HK1220204A1 (zh) -芳基- -亞氨基- -氧代- 噻二嗪
IL237540B (en) Amphiphilic compounds, their preparations and uses
HK1191942A1 (zh) 新型六氫環戊二烯並吡咯酮,六氫吡咯並吡咯酮,八氫吡咯並吡啶酮和八氫吡啶酮化合物
IL237538A0 (en) Amphiphilic compounds, their preparations and uses
IL237539A0 (en) Amphiphilic compounds, their preparations and uses
GB2497001B (en) The hand
GB201207426D0 (en) .
GB201206866D0 (en) .
GB201206865D0 (en) .
GB201205844D0 (en) .
GB201200117D0 (en) .
GB201204383D0 (en) H, level
GB201220276D0 (en) The equi-gleem glove